Echinocandins Combination Therapy for Invasive Aspergillosis
Author Information
Author(s): Yazed Saleh Alsowaida, Bader Alshoumr, Shuroug A. Alowais, Khalid Bin Saleh, Alia Alshammari, Kareemah Alshurtan, Haytham A. Wali
Primary Institution: University of Hail, Saudi Arabia
Hypothesis
Does combining echinocandins with standard antifungal care improve treatment outcomes for invasive aspergillosis?
Conclusion
The study found no significant differences in clinical cure and mortality rates between echinocandins combination therapy and standard monotherapy, but there is a suggestion of better outcomes with the combination.
Supporting Evidence
- The clinical cure rate was not statistically different between echinocandins combination therapy and SOC monotherapy.
- Mortality rates were similar for both treatment groups.
- Adverse drug reactions were not significantly worse in the echinocandins combination group compared to SOC monotherapy.
Takeaway
This study looked at whether using two types of antifungal medicines together helps people with a serious lung infection. It found that using both together didn't work better than just one type.
Methodology
A meta-analysis of ten studies comparing echinocandins combination therapy with standard of care monotherapy for invasive aspergillosis.
Potential Biases
Potential biases from observational studies included in the meta-analysis.
Limitations
The included studies had heterogeneous populations and varied treatment regimens, which may affect the results.
Participant Demographics
Patients included were primarily adults with hematologic malignancies or organ transplants.
Statistical Information
P-Value
p = 0.27 for clinical cure, p = 0.73 for mortality, p = 0.87 for adverse drug reactions.
Confidence Interval
95% CI: 0.75–2.42 for clinical cure, 95% CI: 0.50–1.63 for mortality, 95% CI: 0.49–1.82 for adverse drug reactions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website